Are you interested in taking part in a clinical trial? Our Clinical Trials Directory includes all active clinical trials at The University of Tennessee Medical Center.
Doctors and researchers at The University of Tennessee Medical Center work together diligently. Our goal is to discover new and better ways to find and treat disease. We do this through various research projects and clinical trials.
Research projects at the medical center help move forward medical knowledge. The National Institutes of Health and related agencies fund researchers on our campus to bring the best of medical care to East Tennessee. Plus, our physicians provide clinical trial opportunities for our patients. We make them readily available to those who seek new medications and treatment.
Our research teams work closely with researchers throughout the University of Tennessee system as well as others throughout the nation.
The University of Tennessee Medical Center brings together outstanding patient care, challenging clinical training and stimulating research – all on one campus.
Acute Myeloid Leukemia
Celgene CONNECT – The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Chiesi Ready 1 CUSA-081-HEM-01 – A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs).
Tesaro RUBY 4010-03-001 – A Phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TSR-042 plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with first line stage III/IV or recurrent endometrial cancer in all comers (allows USC and MMMT).
Dr. Reddy’s RI-01-006 Follicular Lymphoma – Phase 3 trial to Compare the Efficacy and Safety of a DRL_RI with MabThera® in patients with previously untreated, Stage II-IV, CD20-positive, low tumor burden follicular lymphoma 1st Line. IP is a proposed biosimilar version of rituximab.
– A Phase III, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma.
Seattle Genetics SGN35-027– A+AVD with G-CSF in Treatment-Naïve Hodgkin Lymphoma (SGN35-027).
Trillium TTI-622-01 – A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.
Amgen Herpetic Infection 20130193 – A post-marketing prospective cohort study of Melanoma patients treated with Imlygic (Talimogene Laherparepvec) in clinical practice to characterize the risk of Herpetic infection among patients, close contacts, and health care providers, and long-term safety in treated patients
Array 818-103 – Phase 1 study to evaluate the effects of Encorafenib in combination with Binimetinib on the pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan administered in a cocktail approach and on the pharmacokinetics of Rosuvastatin in patients with BRAF V600-mutant unresectable or Metastatic BRAF V600-mutant Melanoma or other advanced solid tumors.
Merck MK-3475-716 – A randomized, double-blind phase 3 study of Adjuvant therapy with Pembrolizumab versus Placebo in Resected high risk stage II Melanoma.
Newlink Genetics NLG0304 – Phase 2B study of Ipilimumab with or without Hyperacute-Melanoma (HAM) Immunotherapy for patients with Stage 4 Melanoma.
Altor Biosciences Quilt 3.055 – A Phase 2b, single-arm, multicohort, open-label study of ALT-803 in combination with a PD-1/PD-L1 checkpoint inhibitor in patients who have disease progression following an initial response to treatment in PD-1/PD-L1 checkpoint inhibitor therapy.
Non Small Cell Lung Cancer
Altor Bioscience Quilt 2.023 – A study of ALT-803, a fusion protection activator of natural killer and T-cells, in combination with Pembrolizumab vs Pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer.
AstraZeneca PACIFIC-5 – Phase 3, randomized, open-label, multi-center, international study in patients with locally advanced, unresectable NSCLC who have not progressed following definitive, platinum-based, concurrent chemo-radiation therapy
BrightPath GRN-1201 – A pilot, open-label, multi-center, multi-dose study of GRN-1201 added to Pembrolizumab in subjects with PD-L1+ Non-Small Cell Lung Cancer.
Merck MK-7339-006 – A phase 3 study of Pembrolizumab with maintenance Olaparib or maintenance Pemetrexed in first-line (1L) Metastatic nonsquamous non-small-cell lung cancer.
Galera GTI-4419-301 – A phase 3, randomized, double-blind, placebo-controlled, multi-center study of the Superoxide dismutase mimetic GC4419 to reduce severe oral mucositis (SOM) associated with chemo radiotherapy for locally advanced, non-metastatic head and neck cancer.
Tesaro First – A Phase 3 comparison of platinum-based therapy with TSR-042 and Niraparib versus standard of care platinum -based therapy as first line treatment of Stage III or IV nonmucinous epithelial ovarian cancer.
Lilly 13Y-MC-JPCM – A phase 2, randomized, double-blind, placebo-controlled study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in patients with metastatic-castration-resistant prostate cancer.
Astellas 1948-CL-0101 – A Phase 1b study of ASP1948, targeting an immune modulatory receptor, as a single agent and in combination with Nivolumab in subject with advanced solid tumors.
No trials at this time.
Cutaneous Squamous Cell Carcinoma
Regeneron Case – A prospective survivorship cohort study of adult patients with cutaneous squamous cell carcinoma undergoing treatment with Cemiplimab.
Castle Biosciences CBI-2019-cSCC-PVS-001- Prospective Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma.
BMS/Parexel – PREAMBLE Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation
AstraZeneca PREVAIL – A Prospective, Non-Interventional Study to Assess PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma.
No trials at this time through The Office of Clinical Trials. Contact The Pat Summitt Clinic for information on trials originating there.
Penumbra SURF – Post-market, real world, prospective, multi-center study to demonstrate the safety and efficacy of the Penumbra SMART COIL System, including the WAVE extra soft coils as a fill and finish coil, in the treatment of intracranial aneurysms.
Vanderbilt/Stryker – Framing Eighteen coils in cerebral Aneurysms Trial (FEAT)
Cerenovus CNV-2017-01 – STERLING – A Prospective, Multi-Center, Single Arm Study to obtain “real world” clinical data and characterize the acute and long-term performance of the MICRUSFRAME and GALAXY coils for the endovascular treatment of intracranial aneurysms.
Cerenovus CNV-2017-02 – EXCELLENT post-marketing registry to collect and analyze stroke-inducing blood clots removed from the brain with its Embotrap II revascularization device.
Mayo STRIP – Stroke Thromboembolism Registry of Imaging and Pathology
Endometriosis Associated Pain
ObsEva/Covance OBE2109-002 – A Phase 3 multicenter, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of study drug in subjects with moderate to severe endometriosis associated pain.
Heavy Menstrual Bleeding
Medicines 360 360-L105 – A Phase 3, multicenter, open-label study of a Levonorgestrel 52 mg intrauterine system for the treatment of heavy menstrual bleeding.
MEDNAX OBX-0034 – Impact of a booster course of antenatal steroids on neonatal outcome in patients with premature rupture of the membranes.
End Stage Renal Disease
Humacyte CLN-PRO-V007 – A Phase 3 study to compare the efficacy and safety of Humacyte’s Human Acellular Vessel with that of an Autologous arteriovenous fistula in subjects with End-Stage Renal disease.
Cardiovascular Imaging Agent
GE-265-303 – A Phase 3, Open-label, study of Flupiridaz (18F) injection for Positron Emission Tomography (PET) imaging for assessment of myocardial perfusion in patients referred for invasive coronary angiography because of suspected coronary artery disease.
Vertex/Covance VX17-659-105 – Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who are Homozygous or Heterozygous for the F508del Mutation.
Vertex VX18-445-113 – VX18-445-113 Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis. Sites participating in 105 (above) automatically selected for 113.
V-Wave -RELIEVE – Reducing lung congestion symptoms using the V-Wave shunt in advanced heart failure.
Thyroid Eye Disease
Horizon HZNP-TEP-401 – Phase 3b, multicenter, open-label, single arm expanded access protocol of TEPROTUMUMAB (HZN-001).